Ustekinumab‑srlf bulk supplier for pharma manufacturers

Ustekinumab‑Srlf 45 mg or 90 mg doses Suppliers & Bulk Manufacturers

Available Forms: Subcutaneous injection, Intravenous infusion

Available Strengths: 45 mg or 90 mg doses

Reference Brands: Stelara(US & EU); Imuldosa (ustekinumab-srlf) is a biosimilar of Stelara

Ustekinumab-srlf inhibits interleukins 12 and 23, reducing inflammation and immune response. It effectively treats psoriasis, psoriatic arthritis, and Crohn’s disease. Benefits include long-lasting symptom control, improved quality of life, and targeted therapy, supporting disease management when used under medical supervision.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Ustekinumab (Ustekinumab-srlf) is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality compliant with GMP standards. In the US, FDA approval involves extensive clinical validation and safety assessments. In the EU, CE marking certifies conformity with MDR standards. These products undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical data, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to safe, effective biologic therapies worldwide, supporting optimal management of psoriasis, psoriatic arthritis, and Crohn’s disease.

Ustekinumab‑Srlf — third party manufacturing & bulk supply

Ustekinumab‑Srlf 45 mg or 90 mg doses is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ustekinumab‑Srlf is supplied as Subcutaneous injection, Intravenous infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ustekinumab‑Srlf listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ustekinumab‑Srlf →

Back to Listing

Frequently Asked Questions

Ustekinumab‑srlf is listed as Subcutaneous injection, Intravenous infusion in 45 mg or 90 mg doses. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ustekinumab‑srlf is referenced against Stelara(US & EU); Imuldosa (ustekinumab-srlf) is a biosimilar of Stelara. Reference brands are shown for identification only and remain the property of their respective trademark owners.